Showing results (191-200 of 305) with videos related to
Sort By:
Pageof 31
American Journal of Hematology|January 28, 2022
Health-related quality of life in patients with relapsed/refractory multiple myeloma treated with pomalidomide and dexamethasone ± subcutaneous daratumumab: Patient-reported outcomes from the APOLLO trialEvangelos Terpos, Meletios A Dimopoulos, Mario Boccadoro, et al.Lancet (London, England)|March 15, 2006
Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trialAntonio Palumbo, Sara Bringhen, Tommaso Caravita, et al.Blood|February 5, 2011
Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3Meletios Dimopoulos, Robert Kyle, Jean-Paul Fermand, et al.Haematologica|December 9, 2017
From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectivesFrancesca Gay, Monika Engelhardt, Evangelos Terpos, et al.Oncotarget|October 26, 2016
Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysisStefania Oliva, Manuela Gambella, Milena Gilestro, et al.The Oncologist|May 11, 2012
European perspective on multiple myeloma treatment strategies: update following recent congressesHeinz Ludwig, Hervé Avet-Loiseau, Joan Bladé, et al.Journal of Medical Economics|February 17, 2026
Indirect treatment comparison of DVRd plus DR maintenance (PERSEUS study) versus DVTd or VTd with or without lenalidomide maintenance in transplant-eligible patients with previously untreated multiple myelomaMeletios A Dimopoulos, Mario Boccadoro, Hermann Einsele, et al.The Lancet. Oncology|June 4, 2021
Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trialMeletios A Dimopoulos, Evangelos Terpos, Mario Boccadoro, et al.British Journal of Haematology|January 24, 2014
MET dysregulation is a hallmark of aggressive disease in multiple myeloma patientsAlberto Rocci, Manuela Gambella, Simona Aschero, et al.Hematological Oncology|March 20, 2021
Targeted locus amplification to detect molecular markers in mantle cell and follicular lymphomaElisa Genuardi, Petra Klous, Barbara Mantoan, et al.Pageof 31